Chronic simultaneous inducible nitric oxide synthase (iNOS) and peripheral cannabinoid CB1 receptors blockade ameliorates pulmonary hypertension in monocrotaline-induced rat model
Frontiers in Pharmacology · 26.05.2026 · 17
DOI: 10.3389/fphar.2026.1831802 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 26.05.2026. Verfasst von Piotr Ryszkiewicz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Physiology and Pathophysiology, Medical University of Białystok, Białystok, Poland. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki, Uniwersytet Medyczny w Bialymstoku.
Abstract (Originalsprache)
Background
Pulmonary arterial hypertension (PAH) is a severe multifactorial disease associated with impaired pulmonary hemodynamics, leading to right ventricular (RV) hypertrophy and failure. Induction of inducible nitric oxide synthase (iNOS) and/or activation of cannabinoid CB 1 receptor (CB 1 R) is associated with pro-inflammatory, pro-fibrotic, and pro-hypertrophic effects. Therefore, we tested the effects of chronic simultaneous iNOS/CB 1 R blockade in a rat model of monocrotaline-induced pulmonary hypertension (MCT-PH).
Methods
Rats were injected with monocrotaline or saline (control) and from day 8 after PH induction they received iNOS inhibitor 1400W, peripheral CB 1 R antagonist JD5037, their combination or relevant vehicles for 17 days. Invasive and non-invasive hemodynamic assessments, biochemical and histological analyses were conducted. Moreover, the contractions of isolated right ventricular papillary muscles in response to β-adrenoreceptor agonist were analyzed.
Results
1400W improved MCT-impaired rates in rise/decrease in RV pressure. JD5037 administration reduced MCT-induced increase in mean pulmonary artery pressure (mPAP), RV wall thickness, and improved pulmonary artery Doppler parameters. 1400W + JD5037 combined therapy exerted the most beneficial effects. It reduced RV systolic pressure, mPAP, attenuated RV hypertrophy, with improvement of RV function and blood oxygen saturation. Moreover, it showed anti-inflammatory and anti-remodeling properties. However, no effects on lung hypertrophy, electrocardiographic parameters, and positive inotropic effect of β-adrenoreceptor agonist were revealed.
Conclusion
Our results demonstrated that dual pharmacological iNOS/CB 1 R blockade is more beneficial in MCT-induced PH amelioration than modulation of any single target alone. Therefore, it could be seen as a promising novel PAH treatment strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Experimental Physiology and Pathophysiology, Medical University of Białystok, Białystok, Poland.
Förderung
- Narodowe Centrum Nauki
- Uniwersytet Medyczny w Bialymstoku
Zitieren
APA
Ryszkiewicz, P., Remiszewski, P., Pędzińska-Betiuk, A., Mińczuk, K., Baranowska-Kuczko, M., Weresa, J., & Malinowska, B. (2026). Chronic simultaneous inducible nitric oxide synthase (iNOS) and peripheral cannabinoid CB1 receptors blockade ameliorates pulmonary hypertension in monocrotaline-induced rat model. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1831802
Vancouver
Ryszkiewicz P, Remiszewski P, Pędzińska-Betiuk A, Mińczuk K, Baranowska-Kuczko M, Weresa J, et al. Chronic simultaneous inducible nitric oxide synthase (iNOS) and peripheral cannabinoid CB1 receptors blockade ameliorates pulmonary hypertension in monocrotaline-induced rat model. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1831802
BibTeX
@article{Ryszkiewicz2026,
author = {Ryszkiewicz, Piotr and Remiszewski, Patryk and Pędzińska-Betiuk, Anna and Mińczuk, Krzysztof and Baranowska-Kuczko, Marta and Weresa, Jolanta and Malinowska, Barbara},
title = {Chronic simultaneous inducible nitric oxide synthase (iNOS) and peripheral cannabinoid CB1 receptors blockade ameliorates pulmonary hypertension in monocrotaline-induced rat model},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1831802}
}
EUVIMED